Request Demo

Last update 15 Jul 2025

Itepekimab

Last update 15 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-IL-33 mAb(Regeneron Pharmaceuticals), Immunoglobulin igg4 (230-proline), anti-(human interleukin 33) (human monoclonal regn3500 .gamma.4-chain), disulfide with human monoclonal regn3500 .kappa.-chain, dimer, REGN-3500

+ [1]

Target

IL-33

Action

inhibitors

Mechanism

IL-33 inhibitors(Interleukin-33 inhibitors)

Therapeutic Areas

Respiratory DiseasesInfectious DiseasesOtorhinolaryngologic Diseases

Active Indication

Chronic rhinosinusitis without nasal polypsChronic rhinosinusitis with nasal polypsModerate chronic obstructive pulmonary disease+ [4]

Inactive Indication

Allergic asthmaAsthmaInflammation+ [3]

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Sanofi-Aventis Recherche & Développement SA

Sanofi (China) Investment Co. Ltd.

Regeneron Pharmaceuticals, Inc.

+ [2]

Inactive Organization-

License Organization

Regeneron Pharmaceuticals, Inc.

Sanofi

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 17746027H

Source: *****

Sequence Code 17746031L

Source: *****

Clinical Trials associated with Itepekimab

CTIS2024-515576-12-00

/ RecruitingPhase 2

A randomized, double blind, placebo controlled, Proof of Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps - ACT18421

Start Date20 Mar 2025

Sponsor / Collaborator

Sanofi-Aventis Recherche & Développement SA

NCT06834347

/ RecruitingPhase 3

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older.
Study details include:
* The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks.
* The treatment duration will be up to 52 weeks.
* The number of visits will be 9 site visits and 20 phone/home visits.

Start Date12 Feb 2025

Sponsor / Collaborator

Sanofi

[+1]

NCT06834360

/ RecruitingPhase 3

EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older.
Study details include:
* The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks.
* The treatment duration will be up to 52 weeks.
* The number of visits will be 9 site visits and 20 phone/home visits.

Start Date06 Feb 2025

Sponsor / Collaborator

Sanofi

[+1]

100 Clinical Results associated with Itepekimab

100 Translational Medicine associated with Itepekimab

100 Patents (Medical) associated with Itepekimab

Literatures (Medical) associated with Itepekimab

01 May 2025·Annals of the American Thoracic Society

Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials

Review

Author: Kamel, Ghassan ; Charbek, Edward ; Mohamed, Mohamed M. G.

Rationale: Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality worldwide. Acute exacerbations are associated with progressive decline in lung function and quality of life. After recognition of the role of type 2 inflammation in the pathogenesis of eosinophilic COPD, there was increased interest in studying monoclonal antibodies as a therapeutic agent. Multiple randomized controlled trials showed promising results, yet no consensus exists. Objectives: Our study aims to summarize the current evidence regarding the role of monoclonal antibodies in the management of patients with eosinophilic COPD. Methods: We systematically searched multiple databases using prespecified search terms. We included only randomized controlled trials that compared monoclonal antibodies versus placebo in patients with objective evidence of eosinophilic COPD receiving standard-of-care therapy. The primary outcome of interest was the annualized rate of COPD exacerbation. Absolute changes in forced expiratory volume in 1 second and St. George's Respiratory Questionnaire scores were secondary outcomes. We also reported serious adverse effects and all-cause mortality. Statistical analysis was conducted via random effects model using RevMan software. Results: We identified and included eight double blinded, placebo-controlled trials with a total of 4,512 patients and a median follow up of 52 weeks. The patients' mean age was 65 ± 8 years, with 85% male. Seventy percent of patients were former smokers, with a mean of 43 ± 25 pack-years of smoking history. The majority of patients were receiving triple inhaled therapy. The mean serum eosinophil count at enrollment was 398 ± 297 cells/μl. The monoclonal antibodies studied were dupilumab, mepolizumab, benralizumab, astegolimab, and itepekimab. Compared with placebo, patients who received monoclonal antibodies had a significantly decreased annualized COPD exacerbation rate (rate ratio, 0.79; 95% confidence interval [CI], 0.73-0.86; P < 0.001). The serious adverse effect rate was significantly lower in the monoclonal antibody arm compared with placebo (odds ratio, 0.80; 95% CI, 0.69-0.93; P = 0.004). The all-cause mortality rates were not statistically different between the groups (odds ratio, 0.91; 95% CI, 0.63-1.3; P = 0.6). Dupilumab showed a trend of improved efficacy over mepolizumab and benralizumab. Conclusions: In patients with eosinophilic COPD receiving standard-of-care therapy, the use of monoclonal antibodies led to a significant reduction in annualized COPD exacerbation rate compared with placebo. Monoclonal antibodies have an acceptable tolerability and safety profile.

03 Jan 2025·COPD-Journal of Chronic Obstructive Pulmonary Disease

Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Review

Author: Stanbrook, Matthew ; Blazer, Alina ; Ho, Terence ; Zeraatkar, Dena ; Lupas, Daniel ; Mah, Jasmine ; Pitre, Tyler

BACKGROUND:

Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.

METHODS:

We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD. We performed a random effects frequentist network meta-analysis and present the results using relative risk (RR) and 95% confidence intervals (CI). We used the GRADE framework to rate the certainty of the evidence. Outcomes of interest included exacerbations, change in FEV1, change in quality of life, and serious adverse events.

RESULTS:

Dupilumab reduced exacerbations as compared to placebo (RR 0.68 [95% CI 0.59 to 0.79]) (high certainty). Benralizumab (RR 0.89 [95% CI 0.78 to 1]), itepekimab (RR 0.81 [95% CI 0.61 to 1.07]) and tezepelumab (RR 0.83 [95% CI 0.61 to 1.12]) may reduce exacerbations as compared to placebo (all low certainty). Dupilumab probably reduced exacerbations more than mepolizumab (RR 0.74 [95% CI 0.62 to 0.89]) (moderate certainty). Dupilumab may reduce exacerbations more than tezepelumab (RR 0.82 [95% CI 1.14]) (low certainty). For all patients, no treatment improved FEV1 above the pre-specified minimal clinically important difference (MCID) of 0.1 L. Dupilumab probably has no meaningful effect on FEV1 compared to placebo (MD 0.07 [95% CI 0.02 to 0.13]) (moderate certainty). However, in the subgroup of patients with blood eosinophils ≥300/mcL, both tezepelumab (MD 0.15 [95% CI 0.05 to 0.26]) and dupilumab (MD 0.13 [95% CI 0.06 to 0.19]) probably improved FEV1 above the MCID.

CONCLUSION:

Dupilumab is effective at improving patient-relevant outcomes in COPD with higher eosinophil levels. Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes.

01 Nov 2024·Clinical Pharmacology in Drug Development

Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy Participants

Article

Author: Nivens, Michael C. ; Kosloski, Matthew P. ; Xu, Christine ; Xin, Kong ; Goulaouic, Helene ; Butler, Allison ; Kanamaluru, Vanaja

Abstract:

Itepekimab, a monoclonal antibody against interleukin‐33, has demonstrated clinical utility in previous studies in patients with asthma and chronic obstructive pulmonary disease. An autoinjector (AI) has been developed for administering itepekimab to facilitate further development. This study compared pharmacokinetics of single 300‐mg itepekimab subcutaneous administration via an AI versus a prefilled syringe (PFS). Of 90 healthy volunteers enrolled in this Phase 1, parallel‐design, randomized study and stratified by body weight (50 to <70 kg, ≥70 to <80 kg, ≥80 to 100 kg) and injection site (abdomen, thigh, or arm), 84 completed the study. Systemic exposure of itepekimab was similar for both groups. Point estimates for geometric mean ratios of pharmacokinetic parameters for AI versus PFS groups were 1.01 for maximum serum concentration, 1.06 for area under the serum concentration‐time curve to the last quantifiable concentration, and 1.04 for area under the serum concentration‐time curve extrapolated to infinity. The exposure was similar for both devices in each body weight and injection site subgroup. Overall, systemic exposure of 300‐mg single‐dose itepekimab in healthy participants was comparable when administered subcutaneously via an AI device and PFS, with an acceptable safety profile in both device groups.

News (Medical) associated with Itepekimab

09 Jul 2025

·www.fiercepharma.com

Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre

For the third time in the last five years, Merck has pulled off an acquisition in the $10 to $12 billion range, buying out Verona Pharma and its potential COPD blockbuster Ohtuvayre. Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion for Verona Pharma and its potential blockbuster Ohtuvayre, a first-in-class treatment for chronic obstructive pulmonary disorder (COPD).It is the second-largest deal in biopharma this year, ranking behind Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular, and fits Merck’s pattern of striking every other year with a major transaction.In 2021, Merck spent $11.5 billion for Acceleron and its pulmonary arterial hypertension (PAH) treatment, now known commercially as Winrevair. Then in 2023, the New Jersey company ponied up $10.8 billion for Prometheus and its late-stage bowel disease candidate PRA023.The acquisitions are designed to compensate for the expected loss of patent protection later this decade for cancer superstar Keytruda, which generated $29.5 billion in sales in 2024, accounting for 46% of the company’s revenue.“The sweet spot we see is that $1 to $15-billion range,” Davis said in conference call on Wednesday. “As we’ve also consistently indicated, we’re willing to go beyond that for the right opportunity.”Additionally, Davis said that the company plans to launch roughly 20 “new growth drivers in the coming years, almost all of which have blockbuster potential.” He added that Merck will continue to scout out oncology, immunology and cardiometabolic assets through business development.As for the buyout of Verona, Merck has agreed to pay $107 per share, which is a 23% markup on their price at market close Tuesday and a 39% premium on their 60-day volume-weighted average price. The companies expect the deal to close in the fourth quarter of this year.The FDA approved Ohtuvayre 13 months ago as the first novel inhaled treatment for COPD in more than two decades. The drug can be used as a monotherapy or as an add-on medicine with current steroid therapies. As a selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, Ohtuvayre combines two properties in one medicine, setting it apart from COPD competitors for its ability to both open the airways of patients and reduce their inflammation.Ohtuvayre is off to a solid launch, generating sales of $71 million in the first quarter of this year, good for 95% growth sequentially. During the three months, 25,000 prescriptions were filled, up from 16,000 in 2024.“Since launching Ohtuvayre in August 2024, we have seen rapid and accelerating uptake in the U.S.,” Verona CEO David Zaccardelli said in a release Wednesday. “We believe Merck’s commercial footprint and industry-leading clinical capabilities will help accelerate the potential of Ohtuvayre to reach more patients living with COPD.” The treatment has not been approved in Europe. Some of that advantageous footprint comes through Merck’s commercialization of Winrevair. Although it is a product for a rare lung disease, many of the physicians who prescribe Winrevair will have patients with COPD.The prescriber base for the disease is 14,500 in the U.S., according to Merck’s human health president Jannie Oosthuizen. Verona reported in April that 5,300 doctors had prescribed Ohtuvayre in the first quarter.“I think our scale brings a good ability to expand fairly rapidly into that broader prescriber base, educate and get Ohtuvayre to be added to existing background therapies, especially in those patients with persistent symptoms,” Oosthuizen said, adding that the company expects the market to grow from $17 billion this year to $27 billion by 2032. Meanwhile, other companies are rushing to the COPD space. After a delay, the FDA in May approved GSK's antibody drug Nucala as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential COPD treatment.Last year, Regeneron and Sanofi gained approval for Dupixent to treat COPD exacerbations. The companies also have a second COPD candidate in IL-33 inhibitor itepekimab, which is being tested in two phase 3 trials.

Drug ApprovalAcquisitionPhase 3

03 Jul 2025

·www.biospace.com

Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity

iStock, mouu007 While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing convenience and efficacy. The FDA on Wednesday granted accelerated approval to Regeneron ’s bispecific antibody linvoseltamab for the treatment of patients with relapsed or refractory multiple myeloma. The pharma will market the drug under the brand name Lynozyfic. Analysts at BMO Capital Markets called the approval a “small win” for Regeneron, with Lynozyfic being a “minor contributor to the company’s broader product portfolio.” BMO models around $600 million in potential revenues for Lynozyfic. Regeneron’s bispecific trails other multiple myeloma bispecifics, chief of which is Johnson & Johnson’s Tecvayli , which was approved in 2022, giving it a three-year head start. Regeneron appears to be looking to differentiate in terms of efficacy. Data from the Phase I/II LINKER-MM1 study supported Lynozyfic’s approval, demonstrating a 70% objective response rate, including a 45% complete response rate or better. In a prepared statement on Wednesday, CEO George Yancopoulos said that with this efficacy profile, “Lynozyfic is poised to potentially become a new standard of care for multiple myeloma.” Lynozyfic, a bispecific antibody, works by binding both the BCMA and CD3 proteins, thus directing T cells to destroy multiple myeloma cells. The FDA initially rejected the drug in August 2024, citing manufacturing problems at a third-party fill/finish site. Lynozyfic carries a boxed warning for cytokine release syndrome and neurotoxicity. Uniquely, according to Regeneron’s Wednesday release, Lynozyfic is the first and so far only bispecific with this mode of action that can be dosed every two weeks, with the possibility of extending to every four weeks if a patient achieves very good partial response or better. “Lynozyfic has a convenient response-adapted dosing regimen,” Sundar Jagannath, network director of the Center of Excellence for Multiple Myeloma at Mount Sinai, said in a statement alongside Regeneron’s release. “This is a significant patient-centric advancement that could help reduce treatment burden.” Jagannath served as an investigator on LINKER-MM1. Lynozyfic’s approval on Wednesday is a “step in the right direction” for Regeneron, according to the BMO analysts, who noted that 2025 has so far been a “difficult year” for the pharma. In late May, the company’s shares took a beating after its Dupixent successor itepekimab delivered underwhelming results in the late-stage AERIFY program in chronic obstructive pulmonary disease (COPD). The investigational antibody cleared AERIFY-1, demonstrating a significant 27% reduction in moderate to severe exacerbations in former smokers with inadequately controlled COPD. In AERIFY-2, however, itepekimab failed to hit this same threshold, showing only a 2% reduction in exacerbations at 52 weeks. “Sentiment has undoubtedly been poor for REGN shares of late following the recent itepekimab miss in COPD,” BMO analysts wrote, noting that while Lynozyfic’s approval is an incremental positive for the pharma, “steps are still needed” to restore investor confidence in the company. “But we are encouraged to see a quick win here heading into earnings,” the analysts said.

Drug ApprovalClinical ResultAccelerated Approval

02 Jun 2025

·www.fiercepharma.com

With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B

Sanofi has made its largest acquisition in seven years, buying up Massachusetts rare disease specialist Blueprint Medicines for $9.5 billion. In late April, when Sanofi revealed that it was selling a controlling stake in its consumer health business Opella for 10 billion euros ($11.4 billion), chief financial officer Francois Roger said that the French drugmaker would “explore external growth opportunities for bolt-on acquisitions.”Just five weeks later, Sanofi has made a deal few would describe as “bolt-on,” as it has bought out Massachusetts-based Blueprint Medicines for up to $9.5 billion.With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis (SM) pill Ayvakit, which generated sales of $479 million last year and has peak sales potential of $2 billion, the 14-year-old company projected last year.Blueprint also brings a next-generation SM candidate in elenestinib, a KIT D816V inhibitor which is the subject of a phase 2/3 study, and an early-stage KIT inhibitor BLU-808. KIT plays a central role in mast cell activation, Sanofi said, which is implicated in a broad range of inflammatory diseases.Sanofi is paying $129 per share for the drugmaker, which is a 27% premium over Blueprint’s closing price on May 30 and 34% above its average price over the previous 30 days.The acquisition includes contingent value rights (CVRs) tied to the advancement of BLU-808, which could expand payments to Blueprint shareholders by $2 and $4 per share, bringing the total equity value of the deal from $9.1 billion to $9.5 billion.The Blueprint buyout "complements recent acquisitions of early-stage medicines that remain our main field of interest,” Sanofi CEO Paul Hudson said in a release. “Sanofi still retains a sizeable capacity for further acquisitions.”While Blueprint’s shares jumped by 26% on Monday, Sanofi’s dropped by less than 1%.It is Sanofi’s largest acquisition since its 2018 buyout of hemophilia specialist Bioverativ for $11.8 billion. The Blueprint deal comes after Sanofi made an unsuccessful play in 2022 for another rare disease specialist, Horizon Therapeutics. In that case, Amgen took the prize with its $27.8 billion offer. Sanofi said it anticipates completing the deal in the third quarter and that it will not impact its 2025 financial guidance. The company said in April that it expects (PDF) sales to increase by mid-to-high single digits this year on top of a 9% year-over-year increase in 2024 to 41.1 billion euros ($44.5 billion).The acquisition will help revitalize Sanofi’s portfolio, which has taken a few hits recently. Last week, Sanofi and Regeneron reported the failure of a phase 3 trial of their chronic obstructive pulmonary disorder (COPD) candidate itepekimab. In February, Sanofi revealed a phase 3 trial of its invasive E. coli vaccine came up short. The candidate had been acquired from Johnson & Johnson for $250 million. Sanofi has been active in the M&A market this year, picking up Dren Bio’s clinical-stage bispecific antibody, DR-0201, for $600 million upfront and another $1.3 billion in milestones. Last month, Sanofi spent $470 million for Vigil Neuroscience and its investigative Alzheimer’s disease candidate. And in January, Sanofi paid $2.2 billion for Inbibrx and its human recombinant protein rare disease drug.Other recent Sanofi deals include a $3.2 billion acquisition of Translate Bio in 2021 and a $2.9 billion buyout of Provention Bio in 2023.

AcquisitionPhase 3Vaccine

100 Deals associated with Itepekimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16206

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic rhinosinusitis without nasal polyps	Phase 3	United States	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Japan	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Argentina	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Austria	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Canada	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Chile	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Finland	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Hungary	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Israel	Sanofi	12 Feb 2025
Chronic rhinosinusitis without nasal polyps	Phase 3	Italy	Sanofi	12 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04701983 (AERIFY-1, Company_Website) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive	1,127	itepekimab every two weeks	pdbpdfxwgh(oqhncsxzaa) = xkduwewqzc mekoxlapwo (xstxfsiijh )	Positive	30 May 2025
				Itepekimab every four weeks	pdbpdfxwgh(oqhncsxzaa) = pokuzkfcuw mekoxlapwo (xstxfsiijh )
NCT04751487 (AERIFY-2, Company_Website) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive	-	itepekimab every two weeks	vnptnmticv(drqagsepyf) = smxpnsoezm aqoweoipzt (lnczmillsr )	Negative	30 May 2025
				Itepekimab every four weeks	vnptnmticv(drqagsepyf) = djwyuftphj aqoweoipzt (lnczmillsr )
NCT03546907 (CTgov)	Phase 2	Pulmonary Disease, Chronic Obstructive	343	Any short-acting β agonist as prescribed by treating physician as standard of care (Placebo)	oxudmfecfd = ffqxzsfuri lrahuxjopx (xyfmmairll, orojhgugsn - uxzkzhcmke) View more	-	22 Nov 2022
				Any short-acting β agonist as prescribed by treating physician as standard of care+SAR440340 (SAR440340)	oxudmfecfd = lztrvxnxyq lrahuxjopx (xyfmmairll, gebiodpplf - vlzakbiziv) View more
NCT03738423 (CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	129	Placebo (Placebo Q2W)	tbbwzsnprg(gugkcmyjbe) = texnuegnhk bqdtzuekvq (eqnqjcfeuh, 41.81) View more	-	10 Jun 2022
				REGN3500 (REGN3500 30 mg Q8W)	tbbwzsnprg(gugkcmyjbe) = kmxlehfwyq bqdtzuekvq (eqnqjcfeuh, 31.65) View more
NCT03387852 (CTgov)	Phase 2	Asthma	296	Placebo for dupilumab+Fluticasone+Fluticasone/salmeterol (Placebo)	bhfsfpqkvn = lpchnvdbwr zrklzxbnfx (vuyzctuxpy, jirstxxope - twgiawumug) View more	-	29 Mar 2022
				Dupilumab+Fluticasone+SAR440340+Fluticasone/salmeterol (SAR440340 + Dupilumab)	bhfsfpqkvn = njtzsworuk zrklzxbnfx (vuyzctuxpy, uehrvalyci - lgrbqsoabz) View more
NCT03736967 (CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	206	Placebo (Placebo Q2W)	szyxyskmsa(uukfofkbcz) = anliktbryu fiwlkkmzmo (mxzvvtetgs, 31.86) View more	-	01 Nov 2021
				REGN3500 (REGN3500 300 mg Q2W)	szyxyskmsa(uukfofkbcz) = wzsecamnpt fiwlkkmzmo (mxzvvtetgs, 22.46) View more
NCT03387852 (Pubmed \| N Engl J Med)	Phase 2	Asthma type 2 biomarkers	296	Itepekimab	cklyhoznje(mkgdfknkyu) = Itepekimab treatment improved asthma control and quality of life, as compared with placebo bpppotkiui (dsvjikqxnk ) View more	Positive	28 Oct 2021
				Itepekimab plus Dupilumab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis